111P Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC

J.G. Aerts; L. Paz-Ares; B. Besse; C. Helissey; A. Araújo; D.M. Kowalski; Gilles Quéré; J.C. Benitez; F. Guisier; W. Theelen; Federico Cappuzzo; S. Gadgeel; T.C. Wehler; M.J. Chisamore; Tomer M. Mark; Yanhong Zhou; T.J. Ong; E. Felip

doi:10.1016/j.esmoop.2026.106418

Key Points

This research aims to assess the impact of proactive management on immune-related hepatic adverse events during immunotherapy with acasunlimab and pembrolizumab.
Conducted a phase II clinical trial involving patients with PD-L1 positive mNSCLC.
Utilized acasunlimab (duobody-PD-L1x4-1BB) and pembrolizumab as the treatment regimen.
Implemented proactive management strategies to address immune-related risks.
Demonstrated an acceptable safety profile for the combination therapy.
Proactive management significantly mitigated the incidence of immune-related hepatic adverse events compared to historical data.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase II trial shows proactive management mitigates hepatic adverse events in mNSCLC patients, suggesting enhanced safety.

Abstract

Acasunlimab (Aca; DuoBody-PD-L1x4-1BB) is a bispecific antibody immunotherapy designed to reinvigorate antitumor immunity via conditional 4-1BB activation dependent on co-PD-L1 binding. A ph 2 study of Aca in patients (pts) with PD-L1+ mNSCLC (NCT05117242) showed an acceptable safety and efficacy profile. Given historical immune-related risks with 4-1BB agents, proactive management of immune-related risks (PMIR) was implemented. We report the effects of PMIR on mitigation and management of immune-related hepatic adverse events (IRHAEs).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aerts et al. (2026) studied this question.

synapsesocial.com/papers/69bb9279496e729e6297fdab https://doi.org/10.1016/j.esmoop.2026.106418

View Full Paper

Ask AI

Bookmark

Share

111P Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

111P Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading